. . . . "Drinabant (INN; AVE-1625) es un f\u00E1rmaco que act\u00FAa como un selectivo de CB1 antagonista, que estaba bajo investigaci\u00F3n por Sanofi-Aventis como un tratamiento para la obesidad, la esquizofrenia, la enfermedad de Alzheimer, enfermedad de Parkinson, y dependencia de la nicotina. Aunque estudiada inicialmente como un posible tratamiento para una variedad de diferentes condiciones m\u00E9dicas , Sanofi-Aventis, finalmente, redujo las terap\u00E9uticas indicaciones del compuesto para solo la supresi\u00F3n del apetito . Drinabant alcanz\u00F3 fase IIb de ensayos cl\u00EDnicos para esta finalidad en el tratamiento de la obesidad, pero fue poco despu\u00E9s suspendida,\u200B probablemente debido a la observaci\u00F3n de graves efectos psiqui\u00E1tricos secundarios incluyendo la ansiedad, la depresi\u00F3n y los pensamientos suicidas en pacientes "@es . . . . . . . . . . . . . . . . . . . . "61"^^ . . . . . "Drinabant"@es . "2"^^ . . . "23"^^ . . . . . . . "358970-97-5" . . . . "-N-{1-[Bismethyl]-3-azetidinyl}-N-methanesulfonamide"@en . "IQQBRKLVEALROM-UHFFFAOYSA-N"@en . . . . "Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that wa"@en . . . . . . "358970"^^ . . "5027"^^ . . "1"^^ . "10278470"^^ . . "35805433"^^ . "Fc1ccNSC"@en . . . "10278470" . . "Drinabant ball-and-stick model.png"@en . . . "20"^^ . . . . . . . . . . "None"@en . . . . . "2"^^ . "8453947"^^ . . . . . . . . . . . . "Development terminated"@en . . . . . . . . . . . . . . . . . "Drinabant (INN; AVE-1625) es un f\u00E1rmaco que act\u00FAa como un selectivo de CB1 antagonista, que estaba bajo investigaci\u00F3n por Sanofi-Aventis como un tratamiento para la obesidad, la esquizofrenia, la enfermedad de Alzheimer, enfermedad de Parkinson, y dependencia de la nicotina. Aunque estudiada inicialmente como un posible tratamiento para una variedad de diferentes condiciones m\u00E9dicas , Sanofi-Aventis, finalmente, redujo las terap\u00E9uticas indicaciones del compuesto para solo la supresi\u00F3n del apetito . Drinabant alcanz\u00F3 fase IIb de ensayos cl\u00EDnicos para esta finalidad en el tratamiento de la obesidad, pero fue poco despu\u00E9s suspendida,\u200B probablemente debido a la observaci\u00F3n de graves efectos psiqui\u00E1tricos secundarios incluyendo la ansiedad, la depresi\u00F3n y los pensamientos suicidas en pacientes tratados con la retirada de Rimonabant, otro OC 1 antagonista que tambi\u00E9n estaba siendo desarrollado por Sanofi-Aventis.\u200B"@es . . . . "61S98RLL5I" . "1"^^ . "2"^^ . "2"^^ . "Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis. In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment of (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion of edibles containing large quantities THC and synthetic cannabinoids that are more potent and less expensive than marijuana. Edibles, sold as brownies, cookies and candies, pose particular risks for children, who often consume these by accident. There are currently no approved treatments for ACO."@en . . . . . . . . . "1075450677"^^ . . . . . . . . "Drinabant"@en . .